Pragati Advani1, Abenaa M Brewster2, George P Baum3, Leslie R Schover4. 1. Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. 3. Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston, TX, USA. lschover@gmail.com.
Abstract
PURPOSE: A randomized pilot trial evaluated the hypothesis that early intervention lessens sexual dysfunction in the first year on aromatase inhibitors. A secondary aim was comparing the efficacy of two vaginal moisturizers. METHODS:Fifty-seven postmenopausal women with early stage breast cancer starting aromatase inhibitors were randomized to three treatment groups. All received a handout on managing sexual and other side effects. The Usual Care group received no additional therapy. The Active Treatment groups received a 6-month supply of a vaginal moisturizer (hyaluronic acid-based in Active Group-H and prebiotic in Active Group-P) and a vaginal lubricant and dilator, plus access to an educational website and phone coaching. Questionnaires completed at baseline, 6, and 12 months included the Female Sexual Function Index (FSFI), Menopausal Sexual Interest Questionnaire (MSIQ), Female Sexual Distress Scale-Revised (FSDS-R), and a menopausal symptom scale. RESULTS:Forty-nine women (86%) provided follow-up data. Mean age was 59 and 77% were non-Hispanic Caucasian. Sexual function was impaired at baseline, but remained stable over 12 months for all groups. The combined active treatment group had less dyspareunia (P = 0.07) and sexual distress (P = 0.02) at 6 months than the Usual Care group. At 6 months, the Active-H group improved significantly more than the Active-P group on FSFI total score (P = 0.04). CONCLUSIONS:Sexual counseling helped women maintain stable sexual function on aromatase inhibitors. Active intervention resulted in better outcomes at 6 months. IMPLICATIONS FOR CANCER SURVIVORS: This promising pilot trial suggests a need for more research on preventive counseling to maintain sexual function during aromatase inhibitor treatment.
RCT Entities:
PURPOSE: A randomized pilot trial evaluated the hypothesis that early intervention lessens sexual dysfunction in the first year on aromatase inhibitors. A secondary aim was comparing the efficacy of two vaginal moisturizers. METHODS: Fifty-seven postmenopausal women with early stage breast cancer starting aromatase inhibitors were randomized to three treatment groups. All received a handout on managing sexual and other side effects. The Usual Care group received no additional therapy. The Active Treatment groups received a 6-month supply of a vaginal moisturizer (hyaluronic acid-based in Active Group-H and prebiotic in Active Group-P) and a vaginal lubricant and dilator, plus access to an educational website and phone coaching. Questionnaires completed at baseline, 6, and 12 months included the Female Sexual Function Index (FSFI), Menopausal Sexual Interest Questionnaire (MSIQ), Female Sexual Distress Scale-Revised (FSDS-R), and a menopausal symptom scale. RESULTS: Forty-nine women (86%) provided follow-up data. Mean age was 59 and 77% were non-Hispanic Caucasian. Sexual function was impaired at baseline, but remained stable over 12 months for all groups. The combined active treatment group had less dyspareunia (P = 0.07) and sexual distress (P = 0.02) at 6 months than the Usual Care group. At 6 months, the Active-H group improved significantly more than the Active-P group on FSFI total score (P = 0.04). CONCLUSIONS: Sexual counseling helped women maintain stable sexual function on aromatase inhibitors. Active intervention resulted in better outcomes at 6 months. IMPLICATIONS FOR CANCER SURVIVORS: This promising pilot trial suggests a need for more research on preventive counseling to maintain sexual function during aromatase inhibitor treatment.
Entities:
Keywords:
Aromatase inhibitors; Breast cancer; Dyspareunia; Genitourinary atrophy; Prevention; Sexual dysfunction
Authors: Stacy T Lindau; Joscelyn N Hoffmann; Katie Lundeen; Angela Jaszczak; Martha K McClintock; Jeanne A Jordan Journal: J Gerontol B Psychol Sci Soc Sci Date: 2009-02-09 Impact factor: 4.077
Authors: Jürg Bernhard; Weixiu Luo; Karin Ribi; Marco Colleoni; Harold J Burstein; Carlo Tondini; Graziella Pinotti; Simon Spazzapan; Thomas Ruhstaller; Fabio Puglisi; Lorenzo Pavesi; Vani Parmar; Meredith M Regan; Olivia Pagani; Gini F Fleming; Prudence A Francis; Karen N Price; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Barbara A Walley Journal: Lancet Oncol Date: 2015-06-16 Impact factor: 41.316
Authors: Jeanne Carter; Cara Stabile; Barbara Seidel; Raymond E Baser; Abigail R Gunn; Stephanie Chi; Rebecca F Steed; Shari Goldfarb; Deborah J Goldfrank Journal: Support Care Cancer Date: 2015-01-08 Impact factor: 3.603
Authors: Paul E Goss; James N Ingle; Kathleen I Pritchard; Nicholas J Robert; Hyman Muss; Julie Gralow; Karen Gelmon; Tim Whelan; Kathrin Strasser-Weippl; Sheldon Rubin; Keren Sturtz; Antonio C Wolff; Eric Winer; Clifford Hudis; Alison Stopeck; J Thaddeus Beck; Judith S Kaur; Kate Whelan; Dongsheng Tu; Wendy R Parulekar Journal: N Engl J Med Date: 2016-06-05 Impact factor: 91.245
Authors: J Baumgart; K Nilsson; A Stavreus Evers; T Kunovac Kallak; M M Kushnir; J Bergquist; I Sundström Poromaa Journal: Climacteric Date: 2013-06-28 Impact factor: 3.005
Authors: Giorgio Gandaglia; Nazareno Suardi; Vito Cucchiara; Marco Bianchi; Shahrokh F Shariat; Morgan Roupret; Andrea Salonia; Francesco Montorsi; Alberto Briganti Journal: Transl Androl Urol Date: 2015-04
Authors: Carmen W H Chan; Daria Tai; Stephanie Kwong; Ka Ming Chow; Dorothy N S Chan; Bernard M H Law Journal: Int J Environ Res Public Health Date: 2020-04-24 Impact factor: 3.390